ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 270 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $925 | -16.0% | 44,400 | -3.5% | 0.00% | -20.0% |
| Q2 2023 | $1,101 | -39.5% | 46,000 | -52.5% | 0.01% | +66.7% |
| Q1 2023 | $1,820 | +98.7% | 96,800 | +68.1% | 0.00% | -25.0% |
| Q4 2022 | $916 | -99.9% | 57,600 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $942,000 | -0.4% | 57,600 | -14.3% | 0.00% | 0.0% |
| Q2 2022 | $946,000 | -29.2% | 67,200 | +21.7% | 0.00% | -20.0% |
| Q1 2022 | $1,336,000 | +0.8% | 55,200 | -2.8% | 0.01% | 0.0% |
| Q4 2021 | $1,325,000 | +13.5% | 56,800 | -19.2% | 0.01% | +25.0% |
| Q3 2021 | $1,167,000 | -14.4% | 70,300 | +25.8% | 0.00% | -20.0% |
| Q2 2021 | $1,363,000 | +101.3% | 55,900 | +300.2% | 0.01% | +66.7% |
| Q2 2020 | $677,000 | -59.2% | 13,968 | -64.5% | 0.00% | -66.7% |
| Q1 2020 | $1,660,000 | -5.6% | 39,300 | -4.4% | 0.01% | +28.6% |
| Q4 2019 | $1,758,000 | -39.4% | 41,100 | -49.0% | 0.01% | +16.7% |
| Q3 2019 | $2,900,000 | +124.6% | 80,600 | +66.9% | 0.01% | 0.0% |
| Q2 2019 | $1,291,000 | -5.7% | 48,300 | -5.3% | 0.01% | 0.0% |
| Q1 2019 | $1,369,000 | +825.0% | 51,000 | +862.3% | 0.01% | +500.0% |
| Q1 2016 | $148,000 | -59.2% | 5,300 | -48.0% | 0.00% | -50.0% |
| Q4 2015 | $363,000 | -7.6% | 10,200 | -14.3% | 0.00% | 0.0% |
| Q3 2015 | $393,000 | -52.8% | 11,900 | -40.2% | 0.00% | -50.0% |
| Q2 2015 | $833,000 | +181.4% | 19,900 | +118.7% | 0.00% | +300.0% |
| Q1 2015 | $296,000 | +15.2% | 9,100 | +12.3% | 0.00% | 0.0% |
| Q4 2014 | $257,000 | +99.2% | 8,100 | +55.8% | 0.00% | – |
| Q3 2014 | $129,000 | +460.9% | 5,200 | +420.0% | 0.00% | – |
| Q2 2014 | $23,000 | -91.7% | 1,000 | -91.2% | 0.00% | -100.0% |
| Q1 2014 | $277,000 | +163.8% | 11,400 | +171.4% | 0.00% | – |
| Q4 2013 | $105,000 | -82.0% | 4,200 | -80.2% | 0.00% | -100.0% |
| Q3 2013 | $584,000 | +722.5% | 21,246 | +444.8% | 0.00% | – |
| Q2 2013 | $71,000 | – | 3,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |